CRP and interstitial lung disease: Current standard-of-care for non-IPF ILD focuses on immunosuppression, which has traditionally relied on oral systemic corticosteroids (OCS), such as prednisone, prednisolone and dexamethasone, particularly when inflammatory features are present (e.g., ground-glass opacities (GGOs), 20%–40% BAL lymphocytosis, granulomas, elevated C-reactive protein (CRP)).3,4 International guidelines recommend systemic corticosteroids for acute exacerbation of IPF, based on very low-quality evidence,5 but no such recommendation exists for non-IPF ILD, especially those with PPF.